CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase II Trial of Endocrine Therapy in Combination With OSI-906 (an IGF-1R Inhibitor) and Erlotinib (Tarceva®, an EGFR Inhibitor) in Patients With Hormone-sensitive Metastatic Breast Cancer

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT01205685
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:35:16.279576+00:00
Published At: 2012-09-11T00:00:00+00:00
Record Updated At: 2012-09-11
Results Posted At: 2012-09-11
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Hormone-sensitive Metastatic Breast Cancer"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2012-09-11"
protocolSection.identificationModule.nctId: "NCT01205685"
protocolSection.identificationModule.officialTitle: "A Phase II Trial of Endocrine Therapy in Combination With OSI-906 (an IGF-1R Inhibitor) and Erlotinib (Tarceva\u00ae, an EGFR Inhibitor) in Patients With Hormone-sensitive Metastatic Breast Cancer"
protocolSection.statusModule.overallStatus: "TERMINATED"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2012-09-11"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.